Depodrag®

Injectable suspension.

Steroidal anti-inflammatory.

Dogs and cats.

Each 1 mL of suspension contains:
Triamcinolone Acetonide…………. 6 mg
Excipients q.s.c……………………….1 mL

Depot anti-inflammatory for the treatment of symptoms associated with allergic, dermatological and arthritis disorders.

Dogs and cats:

• In cases of allergy: 0.2 mg of Triamcinolone Acetonide/kg, in single dose. In severe cases it can be administered up to 1 mg of Triamcinolone Acetonide/kg in single dose.
• In intra-articular and intrasynovial treatment: 1 to 3 mg of Triamcinolone Acetonide/kg in a single dose, repeated if necessary after 3 to 4 days.

Dogs and cats:

• In cases of allergy: 0.2 mL each 6 Kg of weight, in single dose. In severe cases it can be administered up to 1 mL each 6 Kg of weight, in single dose.
• In intra-articular and intrasynovial treatment: 0.2 to 0.5 mL, in a single dose, repeated if necessary after 3 to 4 days.

It is not recommended to repeat the treatment more than 3 consecutive times.

Intramuscular, subcutaneous, intra-articular and intrasynovial.

Long-term use of Depodrag^® may cause suppressive effects on the hypothalamic-pituitary-adrenal axis leading to adrenal atrophy (adrenal insufficiency). It can also cause bone resorption or inhibition of bone growth and repair, inhibition of collagen synthesis, decreased growth rate, delayed wound healing, diarrhea, gastrointestinal irritation, gastrointestinal ulceration, hematopoietic changes, sodium and fluid retention, and exacerbation of latent infections.
The most frequent side effects are polyuria, polydipsia, polyphagia, lethargy, weakness, and bilateral alopecia.

Less common are weight loss, anorexia, and diarrhea.

• In bacterial infections, the use should be associated with antibacterials.
• Corticosteroids can precipitate labor during late gestation.
• Shake before use.
• Keep out of reach of children and pets.

• Do not use in viral infectious processes and generalized fungal infections.
• Do not use in animals with tuberculosis, chronic nephritis, or Cushing’s syndrome, except for emergency therapy.
• Do not use in case of bone metaplasia and osteoporosis.
• Do not use in musculoskeletal disorders where immobility is required.
• Do not use in patients with Diabetes Mellitus, renal or cardiac insufficiency.
• Do not use in animals with gastrointestinal or corneal ulcer.
• Do not use in patients with hypersensitivity to the active substance.

• Do not use in pregnant and lactating females.
• Glucocorticoids are probably needed for normal fetal development. They may be required for proper surfactant production and development of myelin, retina, pancreas, and breasts.
• Excessive doses early in gestation can lead to teratogenic effects. Administration of exogenous steroids may induce labor when used in late pregnancy. It is recommended not to use high doses in pregnant animals.
• Glucocorticoids not bound to plasma proteins enter the milk. High doses, or prolonged administration in mothers, can potentially inhibit the growth of newborns.

• Amphotericin B or caliuretic diuretics (furosemide, thiazides) may cause hypokalemia when administered concomitantly with glucocorticoids. When these drugs are used concurrently with digitalis glycosides, the possibility of toxicity may increase if hypokalemia occurs. Diligent monitoring of potassium and digitalis levels is recommended.
• Glucocorticoids can reduce blood levels of salicylates.
• Insulin requirements may be increased in patients receiving glucocorticoids.
• Phenytoin, Phenobarbital, Rifampicin may increase glucocorticoid metabolism.
• Concomitant administration of glucocorticoids and cyclosporine may increase blood levels of each, with mutual inhibition of hepatic metabolism. The clinical significance of this interaction is uncertain. Glucocorticoids may also inhibit hepatic metabolism of cyclophosphamide. Dosage adjustments may be required.
• Mitotane can alter steroid metabolism; Higher than usual doses may be needed to treat mitotane-induced adrenal insufficiency.
• Patients treated with corticosteroids at immunosuppressive doses should not receive live attenuated live virus vaccines because viral replication may be enhanced. A diminished immune response may occur after administration of a vaccine, toxoid, or bacterin, in patients receiving glucocorticoids.
• Administration of ulcerogenic drugs (e.g., nonsteroidal anti-inflammatory drugs) with glucocorticoids may increase the risk of gastrointestinal ulceration.
• The effects of hydrocortisone, and possibly other glucocorticoids, may be potentiated by concomitant administration with estrogens.
• In patients with myasthenia gravis, concomitant administration of glucocorticoids and anticholinesterases (e.g., pyridostigmine, neostigmine, etc.) may induce pronounced muscle weakness. If possible, discontinue anticholinesterase medication at least 24 hours before glucocorticoid administration

• Do not handle by pregnant women.
• In case of contact with skin, eyes or mucous membranes, wash immediately with plenty of water.
• In case of accidental ingestion, seek medical attention immediately and show internal product leaflet.
• In case of accidental injection, go immediately to a medical center and show internal product leaflet.

Dispose of waste of this product with caution along with household waste. Do not dispose of containers with product residues on the ground or in waterways. For expired or unused products, contact the manufacturing laboratory. For Uruguay: Dispose of containers at the nearest collection center.

Store at room temperature below 25°C. Do not freeze. Once opened, use within 28 days. Discard the unused product after that period of time. For export: Store at room temperature below 30 °C.

Sale by prescription to the Veterinary Doctor.

Ampoule bottle with 5 mL and 20 mL

Chile: Reg. SAG No 529
Uruguay: Reg. MGAP N° A-4493
Rep. Dominican: Reg. No 5607
Bolivia: Reg. SENASAG PUV-F-N° 005515/13
Peru: Reg. SENASA F.06.42.I.0240

Laboratorio Drag Pharma Chile Invetec S.A.
Lautaro N° 300. Quilicura. Santiago. Chile.